GSK-256066
- Generic Name
- GSK-256066
- Drug Type
- Small Molecule
- Chemical Formula
- C27H26N4O5S
- CAS Number
- 801312-28-7
- Unique Ingredient Identifier
- 2D6GK059SR
- Background
Gsk256066 has been used in trials studying the treatment and diagnostic of SAR, Asthma, Mild Asthma, Allergic Rhinitis, and Seasonal Allergic Rhinitis, among others.
A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 55
- Registration Number
- NCT00612820
- Locations
- 🇦🇹
GSK Investigational Site, Vienna, Austria
A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
Phase 2
Completed
- Conditions
- Allergic RhinitisRhinitis, Allergic, Seasonal
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00612118
- Locations
- 🇦🇹
GSK Investigational Site, Vienna, Austria
Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 104
- Registration Number
- NCT00549679
- Locations
- 🇸🇰
GSK Investigational Site, Martin, Slovakia
Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78
- Registration Number
- NCT00549744
- Locations
- 🇿🇦
GSK Investigational Site, Bloemfontein, South Africa
Endotoxin Challenge Study For Healthy Men and Women
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 37
- Registration Number
- NCT00515268
- Locations
- 🇩🇪
GSK Investigational Site, Hannover, Niedersachsen, Germany
A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00464568
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00445510
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, SeasonalSeasonal Allergic Rhinitis
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT00430157
- Locations
- 🇦🇹
GSK Investigational Site, Vienna, Austria
Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma
Phase 2
Completed
- Conditions
- AsthmaMild Asthma
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11
- Registration Number
- NCT00380354
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, SeasonalSeasonal Allergic Rhinitis
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 44
- Registration Number
- NCT00377728
- Locations
- 🇦🇹
GSK Investigational Site, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath